| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 1,328,841 | 1,385,359 | ||
| Prepaid expenses | 152,033 | 175,783 | ||
| Total current assets | 1,480,874 | 1,561,142 | ||
| Long-term prepaid insurance | 0 | 37,758 | ||
| Cash held in trust account | 199,769,089 | 197,576,768 | ||
| Total assets | 201,249,963 | 199,175,668 | ||
| Accounts payable and accrued expenses | 414,107 | 381,554 | ||
| Accrued offering costs | -90,000 | -90,000 | ||
| Due to related party | -710,857 | -635,857 | ||
| Promissory note - related party | 11,824 | 11,824 | ||
| Total current liabilities | 1,226,788 | 1,119,235 | ||
| Deferred legal fees | 299,088 | 299,088 | ||
| Deferred underwriting fee payable | 6,719,660 | 6,719,660 | ||
| Total liabilities | 8,245,536 | 8,137,983 | ||
| Classa ordinary shares subject to possible redemption, 0.0001 par value 19,199,029 issued and outstanding as of september30, 2025 and december31, 2024 at redemption value of 10.41 and 10.08 per share as of september30, 2025 and december31, 2024, respectively | 199,769,089 | 197,576,768 | ||
| Common stock value-Common Class A | 58 | 58 | ||
| Common stock value-Common Class B | 480 | 480 | ||
| Additionalpaid-incapital | 0 | 0 | ||
| Accumulated deficit | -6,765,200 | -6,539,621 | ||
| Total shareholders' deficit | -6,764,662 | -6,539,083 | ||
| Total liabilities, class a ordinary shares subject to possible redemption and shareholders' deficit | 201,249,963 | 199,175,668 | ||
Oaktree Acquisition Corp. III Life Sciences (OACC)
Oaktree Acquisition Corp. III Life Sciences (OACC)